<DOC>
	<DOCNO>NCT00981630</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , immunogenicity new formulation lyophilise ChimeriVax™-JE , give three dose level , compare placebo . Primary Objectives : Safety : - To obtain safety tolerability data single subcutaneous vaccination ChimeriVax™-JE , three dose level , healthy adult volunteer ( 18-49 year old ) . Immunogenicity : - To obtain data antibody response single subcutaneous vaccination ChimeriVax™-JE , three dose level , healthy adult volunteer without prior Japanese encephalitis immunity . - To assess durability immune response 12 month follow single subcutaneous vaccination ChimeriVax™-JE , three dose level .</brief_summary>
	<brief_title>Study Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine</brief_title>
	<detailed_description>All participant receive single dose study vaccine , ChimeriVax™-JE placebo Day 0 . The double-blind treatment phase last 30 day , follow-up visit 6 12 month .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : All aspect protocol explain write informed consent obtain participant . Aged ≥18 &lt; 49 year . In good general health , without significant medical history , physical examination finding , clinically significant abnormal laboratory result . Participant must available study duration , include plan followup visit . Participant must agree take follow precaution avoid insect bite 7 day follow vaccination use N , Ndiethylmetatoluamide ( DEET ) contain insect repellent , appropriate . For female participant : Negative pregnancy test Screening Day 0 , conjunction menstrual contraceptive history indicate low probability pregnancy opinion physician . Females childbearing potential require correctly use efficacious hormonal method contraception intrauterine device least 1 month randomisation onstudy phase Day 30 . Barrier method contraception consider acceptable study entry . Female participant childbearing potential sign agreement contraception correctly practise specify period specify method use . Female participant unable become pregnant must document ( e.g. , tubal ligation , hysterectomy postmenopausal [ least one year since last menstrual period ] ) . Exclusion Criteria : A history vaccination infection Japanese encephalitis ( JE ) yellow fever ( YF ) flavivirus ( include Japanese encephalitis , tickborne encephalitis , St Louis encephalitis , West Nile virus , dengue fever , Murray Valley encephalitis ) . Previous vaccination determine history ( interview subject ) . Previous current military service . History residence travel flavivirus endemic area tropic ( Cape York region Northern Queensland , India , Southeast Asia , Central America , Caribbean South America ) periods 4 week . Known suspect immunodeficiency ( e.g. , human immunodeficiency virus [ HIV ] infection , primary immunodeficiency disorder , leukemia , lymphoma ) , use immunosuppressive antineoplastic drug ( corticosteroid &gt; 10 mg prednisone , equivalent , last three month trial ( Day 30 ) . History thymoma , thymic surgery ( removal ) myasthenia gravis . Clinically significant abnormality laboratory assessment ( i.e. , meet mild , moderate severe criterion describe toxicity grading laboratory value ) . Anaphylaxis serious adverse reaction characterise urticaria angioedema food , hymenoptera ( bee family ) sting , drug ( include vaccine ) . Transfusion blood treatment blood product , include intramuscular intravenous serum globulin within six month Screening Visit Day 30 . Administration another vaccine antiviral within 30 day precede screening visit Day 30 ( subject reschedule vaccination later date ) . Physical examination indicate clinically significant medical condition . Body temperature &gt; 38.1°C ( 100.6°F ) acute illness within 3 day prior inoculation ( participant may reschedule ) . Intention travel area prior study visit Day 30 . Seropositive hepatitis C virus HIV positive Hepatitis B Surface Antigen . Lactation intend pregnancy female subject . Excessive alcohol consumption , drug abuse , significant psychiatric illness . A know suspected physiological structural condition compromise integrity bloodbrain barrier ( e.g. , significant hypertensive cerebrovascular disease , trauma , ischaemia , infection , inflammation brain ) . Intention increase normal exercise routine , participate contact sport strenuous weight lift initiate vigorous exercise Screening Day 30 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>ChimeriVax™-JE Vaccine</keyword>
	<keyword>Adult</keyword>
</DOC>